Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651459 | 1.00 | LMNA (0.62) | LMNASYKHSP90AA1HSP90AB1TTR | |
| SCHEMBL15225947 | 0.90 | HSP90AA1 (0.58) | LMNASYKHSP90AA1HSP90AB1HDAC4 | |
| SCHEMBL4602802 | 0.88 | HDAC4 (0.62) | LMNAHDAC4HDAC2HDAC8CA12 | |
| SCHEMBL29460667 | 0.87 | PARP1 (0.62) | LMNASYKHSP90AA1HSP90AB1HDAC4 | |
| SCHEMBL6934114 | 0.87 | HSP90AA1 (0.58) | LMNASYKHSP90AA1HSP90AB1HDAC4 | |
| SCHEMBL402416 | 0.86 | CA12 (0.62) | LMNASYKTTRCA12CA1 | |
| SCHEMBL2744367 | 0.85 | MAPT (0.54) | LMNASYKKDM4EALDH1A1CYP2C8 | |
| SCHEMBL21880568 | 0.84 | LMNA (0.56) | LMNATTRCA12CA1CA2 | |
| SCHEMBL6246669 | 0.84 | PDE4D (0.54) | LMNAHSP90AA1HSP90AB1TTRCA12 | |
| SCHEMBL6248458 | 0.83 | LMNA (0.68) | LMNASYKTTRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113896701-A | Synthesis process of Hsp90 inhibitor KU-177 | 南京中医药大学 | 2022-01-07 | — | — | CN | claimed |
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-06-02 | — | — | US | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| CN-113896701-A | Synthesis process of Hsp90 inhibitor KU-177 | 南京中医药大学 | 2022-01-07 | — | — | CN | disclosed |
| CN-113896701-A | Synthesis process of Hsp90 inhibitor KU-177 | 南京中医药大学 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020207396-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168427-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, RPS27A, HSPBP1 | LMNA 1653/4885SYK 3591/4885HSP90AA1 44/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | LMNA 4561/4885SYK 751/4885HSP90AA1 4/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | LMNA 1560/4885SYK 2849/4885HSP90AA1 292/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | LMNA 3367/4885SYK 878/4885HSP90AA1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.